The global mice model market is entering a transformative phase in biomedical research and drug development. Valued at US$1.53 billion in 2024, the market rose to US$1.70 billion in 2025 and is projected to grow at a CAGR of 10.0% from 2025 to 2030, reaching US$2.74 billion by 2030. This remarkable growth reflects the critical role that mice models play in preclinical studies, oncology research, genetic engineering, and personalized medicine.
As the life sciences industry continues to focus on precision therapies, clinical validation, and faster drug discovery, mice remain a cornerstone of modern research thanks to their genetic similarity to humans, reproducibility, and versatility.
Market Growth Insights & Trends
The mice model market is witnessing accelerated adoption across pharmaceuticals, biotechnology, and academic institutions. Key trends shaping the market include:
- Rising adoption of mice models in preclinical research due to their genetic and physiological versatility.
- Increased demand for mouse clinical trials as regulatory authorities and researchers seek cost-effective, predictive models.
- Expansion of personalized medicine in oncology, where humanized mice are essential for immuno-oncology studies.
- Advancements in genetic engineering technologies, such as CRISPR-Cas9, which enable the creation of genetically engineered mice for disease-specific research.
This growth positions the mice model industry as a crucial enabler of drug discovery, cancer research, and translational medicine over the next decade.
Key Market Drivers
- Personalized Medicine in Oncology
With the rise of precision oncology, researchers are using humanized mice models to test patient-specific therapies. This is driving demand for mice models in clinical oncology trials.
- Advancements in Genetic Engineering
The integration of CRISPR-Cas9 and transgenic technologies allows scientists to engineer mice with specific genetic profiles, making them essential tools for studying rare diseases, immune disorders, and cancer pathways.
- Cost-Effective & Scalable Research Models
Compared to primates and other animal models, mice offer scalability, cost-effectiveness, and ethical flexibility, making them a preferred choice in preclinical drug evaluation.
- Expanding Use in Immunology & Infectious Disease Research
Post-pandemic, mice are increasingly used in vaccine development and immunology studies, further fueling market expansion.
Challenges & Opportunities
Challenges
- Ethical concerns surrounding animal testing.
- Regulatory hurdles across different countries.
- Availability of alternatives such as organoids and in-vitro models.
Opportunities
- Growing focus on 3D humanized mice models for more predictive outcomes.
- Partnerships between CROs (Contract Research Organizations) and pharmaceutical giants.
- Rising demand in emerging markets with expanding biotech sectors.
Competitive Landscape
The global mice model market is highly competitive, with players focusing on product innovation, genetic engineering, and strategic collaborations. Key companies include:
- Charles River Laboratories
- Taconic Biosciences
- Envigo
- Janvier Labs
- The Jackson Laboratory
- Harbour BioMed
These companies are investing heavily in genetically engineered and humanized mice, catering to pharmaceutical, biotech, and research institutions worldwide.
Future Outlook to 2030
The future of the mice model market is closely tied to advancements in genomic editing, oncology therapeutics, and AI-driven drug discovery. By 2030, the industry will see:
- Broader adoption of humanized mice for personalized medicine applications.
- Integration of AI & digital modeling with mice research to accelerate drug development.
- Expansion into emerging economies where biotech investments are increasing.
The forecasted US$2.74 billion valuation by 2030 highlights the sector’s resilience and its indispensable role in healthcare innovation.
Conclusion
The mice model market is not just growing—it is evolving. With applications in oncology, immunology, genetics, and personalized medicine, mice remain a critical research tool for the pharmaceutical and biotechnology industries.
👉 For pharma companies, CROs, and investors, this market presents significant growth opportunities through partnerships, innovation, and expanding R&D investments.
For more information, Inquire Now!
FAQs (SEO-Boost Section)
Q1. What is the size of the global mice model market?
The market is valued at US$1.70 billion in 2025 and is expected to reach US$2.74 billion by 2030, growing at a CAGR of 10.0%.
Q2. Why are mice models widely used in research?
Mice are genetically and physiologically similar to humans, making them ideal for preclinical studies, oncology trials, and genetic engineering research.
Q3. What are the key drivers of the mice model market?
The market is driven by the rising demand for personalized medicine, growth in oncology research, advancements in genetic engineering, and increased preclinical testing.
Q4. Who are the leading players in the mice model industry?
Major players include Charles River Laboratories, Taconic Biosciences, Envigo, The Jackson Laboratory, and Janvier Labs.
Q5. What is the future of mice models in drug discovery?
By 2030, humanized mice and CRISPR-engineered models will dominate the landscape, enabling faster, more accurate, and patient-specific therapies.